{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:36:05Z","timestamp":1757612165874,"version":"3.44.0"},"reference-count":86,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To provide an update of recent advancements in pediatric hepatology, highlighting new diagnostic criteria, emerging therapeutic options, and molecular insights into liver diseases which are reshaping clinical practice and guiding future research<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Nonalcoholic fatty liver disease (NAFLD) has been redefned as metabolic dysfunction-associated steatotic liver disease (MASLD), reflecting an improved understanding of its underlying pathophysiology. Advances in immunophenotyping have identified activated T-cell hepatitis as a significant contributor to indeterminate pediatric acute liver failure. Additionally, the introduction of ileal bile acid transporter (IBAT) inhibitors marks a transformative shift in the management of pediatric cholestatic diseases including Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), offering improved growth, quality of life, and native liver survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Recent developments in pediatric hepatology are changing how liver diseases are approached in clinical practice. Evolving disease classifications, expanded use of genetic and immunologic profiling, and the introduction of novel therapies mark a shift toward more individualized care. Ongoing research is needed to evaluate long-term outcomes and ensure that these advances translate into durable improvements for children with liver disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001489","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T10:00:44Z","timestamp":1755511244000},"page":"457-465","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The evolving landscape of pediatric hepatology: key updates and future directions"],"prefix":"10.1097","volume":"37","author":[{"given":"Paul","family":"Lu","sequence":"first","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition, Hassenfeld Children's Hospital, New York University Langone Hospitals"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Ovchinsky","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition, Hassenfeld Children's Hospital, New York University Grossman School of Medicine, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Goldner","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition, Hassenfeld Children's Hospital, New York University Grossman School of Medicine, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"R1-20250904","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MPG.0000000000001482","article-title":"NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN)","volume":"64","author":"Vos","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R2-20250904","doi-asserted-by":"crossref","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann Hepatol"},{"key":"R3-20250904","doi-asserted-by":"crossref","first-page":"100485","DOI":"10.1016\/j.jlr.2023.100485","article-title":"From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease","volume":"65","author":"Rinella","year":"2024","journal-title":"J Lipid Res"},{"key":"R4-20250904","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis"},{"key":"R5-20250904","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5009\/gnl240407","article-title":"Genetic risk factors for metabolic dysfunction-associated steatotic liver disease","volume":"19","author":"Pei","journal-title":"Gut Liver"},{"key":"R6-20250904","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2025.02.033","article-title":"Integrative metabolism in MASLD and MASH: pathophysiology and emerging mechanisms","volume":"83","author":"Steinberg","year":"2025","journal-title":"J Hepatol"},{"key":"R7-20250904","doi-asserted-by":"crossref","first-page":"9729107","DOI":"10.1155\/2017\/9729107","article-title":"Diagnostic value of CK-18, FGF-21, and related biomarker panel in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"2017","author":"He","year":"2017","journal-title":"Biomed Res Int"},{"key":"R8-20250904","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jpn3.12068","article-title":"Noninvasive scores are poorly predictive of histological fibrosis in paediatric fatty liver disease","volume":"78","author":"Kalveram","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R9-20250904","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/apt.12518","article-title":"Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected nonalcoholic fatty liver disease","volume":"38","author":"Schwimmer","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R10-20250904","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/hep.31317","article-title":"Alanine aminotransferase and gamma-glutamyl transpeptidase predict histologic improvement in pediatric nonalcoholic steatohepatitis","volume":"73","author":"Newton","year":"2021","journal-title":"Hepatology"},{"key":"R11-20250904","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/HEP.0000000000000843","article-title":"AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"key":"R12-20250904","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/chi.2022.0136","article-title":"Clinical performance of transient elastography with comparison to quantitative magnetic resonance imaging, ultrasound, and biopsy in children and adolescents with known or suspected fatty liver disease","volume":"19","author":"V.","year":"2023","journal-title":"Child Obes"},{"key":"R13-20250904","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/hep.22376","article-title":"Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis","volume":"48","author":"Nobili","year":"2008","journal-title":"Hepatology"},{"key":"R14-20250904","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/liv.12024","article-title":"Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease","volume":"33","author":"Alkhouri","year":"2013","journal-title":"Liver Int"},{"key":"R15-20250904","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jpeds.2013.04.044","article-title":"Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children's hospital experience","volume":"163","author":"Lee","year":"2013","journal-title":"J Pediatr"},{"key":"R16-20250904","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/RLI.0000000000000529","article-title":"Tomoelastography for the evaluation of pediatric nonalcoholic fatty liver disease","volume":"54","author":"Hudert","year":"2019","journal-title":"Invest Radiol"},{"key":"R17-20250904","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1148\/radiol.2016161002","article-title":"Liver stiffness in pediatric patients with fatty liver disease: diagnostic accuracy and reproducibility of shear-wave elastography","volume":"283","author":"Garcovich","year":"2017","journal-title":"Radiology"},{"key":"R18-20250904","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/hep.29241","article-title":"Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease","volume":"66","author":"Schwimmer","year":"2017","journal-title":"Hepatology"},{"key":"R19-20250904","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1148\/radiol.2018172099","article-title":"Diagnostic performance of MR elastography for liver fibrosis in children and young adults with a spectrum of liver diseases","volume":"287","author":"Trout","year":"2018","journal-title":"Radiology"},{"key":"R20-20250904","doi-asserted-by":"crossref","first-page":"784221","DOI":"10.3389\/fped.2021.784221","article-title":"Magnetic resonance imaging-proton density fat fraction vs. transient elastography-controlled attenuation parameter in diagnosing nonalcoholic fatty liver disease in children and adolescents: a meta-analysis of diagnostic accuracy","volume":"9","author":"Jia","year":"2021","journal-title":"Front Pediatr"},{"key":"R21-20250904","doi-asserted-by":"crossref","DOI":"10.1002\/jmri.29756","article-title":"MR and ultrasound for liver fat assessment in children: techniques and supporting evidence","author":"Serai","year":"2025","journal-title":"J Magn Reson Imaging"},{"key":"R22-20250904","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/hep.29596","article-title":"Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease","volume":"67","author":"Middleton","year":"2018","journal-title":"Hepatology"},{"key":"R23-20250904","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jpn3.12402","article-title":"Pharmacological management of pediatric metabolic dysfunction-associated steatotic liver disease","volume":"80","author":"Abou Jaoudeh","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R24-20250904","doi-asserted-by":"crossref","first-page":"100164","DOI":"10.1016\/j.obpill.2025.100164","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) in children with obesity: an Obesity Medicine Association (OMA) and expert joint perspective 2025","volume":"14","author":"Panganiban","year":"2025","journal-title":"Obes Pillars"},{"key":"R25-20250904","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with LIVER fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"R26-20250904","first-page":"133","article-title":"Recent data from the ESSENCE trial on semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"21","author":"Alkhouri","year":"2025","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R28-20250904","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"R29-20250904","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R30-20250904","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A Randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"key":"R31-20250904","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa2407379","article-title":"Liraglutide for children 6 to <12 years of age with obesity \u2013 a randomized trial","volume":"392","author":"Fox","year":"2025","journal-title":"N Engl J Med"},{"key":"R32-20250904","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"key":"R33-20250904","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jpeds.2005.12.051","article-title":"Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group","volume":"148","author":"Squires","year":"2006","journal-title":"J Pediatr"},{"key":"R34-20250904","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.cld.2022.03.007","article-title":"An update on pediatric acute liver failure: emerging understanding of the impact of immune dysregulation and novel opportunities for intervention","volume":"26","author":"Kulkarni","year":"2022","journal-title":"Clin Liver Dis"},{"key":"R35-20250904","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/MPG.0000000000002893","article-title":"Activated CD8 T-cell hepatitis in children with indeterminate acute liver failure: results from a multicenter cohort","volume":"71","author":"Chapin","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R36-20250904","doi-asserted-by":"crossref","first-page":"e0286394","DOI":"10.1371\/journal.pone.0286394","article-title":"Effector memory CD8 T-cells as a novel peripheral blood biomarker for activated T-cell pediatric acute liver failure","volume":"18","author":"Chapin","year":"2023","journal-title":"PLoS One"},{"key":"R37-20250904","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.31271","article-title":"Four biomarkers linked to activation of cluster of differentiation 8-positive lymphocytes predict clinical outcomes in pediatric acute liver failure","volume":"73","author":"Leonis","year":"2021","journal-title":"Hepatology"},{"key":"R38-20250904","doi-asserted-by":"crossref","first-page":"102407","DOI":"10.1016\/j.clinre.2024.102407","article-title":"Identification of pediatric activated T-cell hepatitis using clinical immune studies","volume":"48","author":"Chapin","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R39-20250904","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/hep4.1726","article-title":"Transcriptional analysis of liver tissue identifies distinct phenotypes of indeterminate pediatric acute liver failure","volume":"5","author":"Chapin","year":"2021","journal-title":"Hepatol Commun"},{"key":"R40-20250904","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jaci.2024.08.029","article-title":"Systemic T-cell activation and IFN-gamma activity in indeterminate severe hepatitis are reminiscent of hemophagocytic lymphohistiocytosis: Implications for T-cell- and IFN-gamma-directed therapies","volume":"155","author":"Nguyen","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"R41-20250904","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/j.1600-6143.2004.00559.x","article-title":"Early evidence of bone marrow dysfunction in children with indeterminate fulminant hepatic failure who ultimately develop aplastic anemia","volume":"4","author":"Molina","year":"2004","journal-title":"Am J Transplant"},{"key":"R42-20250904","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/petr.12296","article-title":"Novel protocol including liver biopsy to identify and treat CD8+ T-cell predominant acute hepatitis and liver failure","volume":"18","author":"McKenzie","year":"2014","journal-title":"Pediatr Transplant"},{"key":"R43-20250904","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jpeds.2018.12.042","article-title":"Corticosteroid therapy for indeterminate pediatric acute liver failure and aplastic anemia with acute hepatitis","volume":"208","author":"Chapin","year":"2019","journal-title":"J Pediatr"},{"key":"R44-20250904","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jhep.2024.04.006","article-title":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on genetic cholestatic liver diseases","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"R45-20250904","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/MOP.0000000000001380","article-title":"What's new in pediatric genetic cholestatic liver disease: advances in etiology, diagnostics and therapeutic approaches","volume":"36","author":"Pinon","year":"2024","journal-title":"Curr Opin Pediatr"},{"key":"R46-20250904","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MPG.0000000000001334","article-title":"Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition","volume":"64","author":"Fawaz","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R47-20250904","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/MPG.0000000000003094","article-title":"Use of a comprehensive 66-gene cholestasis sequencing panel in 2171 cholestatic infants, children, and young adults","volume":"72","author":"Karpen","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R48-20250904","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13023-025-03599-2","article-title":"Genotypes and different clinical variants between children and adults in progressive familial intrahepatic cholestasis: a state-of-the-art review","volume":"20","author":"Vitale","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"R49-20250904","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jhep.2020.02.007","article-title":"Genotype correlates with the natural history of severe bile salt export pump deficiency","volume":"73","author":"van Wessel","year":"2020","journal-title":"J Hepatol"},{"key":"R50-20250904","doi-asserted-by":"crossref","first-page":"100626","DOI":"10.1016\/j.jhepr.2022.100626","article-title":"Genotype-phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency","volume":"5","author":"Felzen","year":"2023","journal-title":"JHEP Rep"},{"key":"R51-20250904","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31787","article-title":"Impact of genotype, serum bile acids, and surgical biliary diversion on native liver survival in FIC1 deficiency","volume":"74","author":"van Wessel","year":"2021","journal-title":"Hepatology"},{"key":"R52-20250904","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","article-title":"Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial","volume":"7","author":"Thompson","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R53-20250904","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S2468-1253(24)00074-8","article-title":"Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"9","author":"Ovchinsky","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R54-20250904","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1002\/hep4.1980","article-title":"Maralixibat for the treatment of PFIC: Long-term, IBAT inhibition in an open-label, Phase 2 study","volume":"6","author":"Loomes","year":"2022","journal-title":"Hepatol Commun"},{"key":"R55-20250904","doi-asserted-by":"crossref","first-page":"e16201","DOI":"10.1111\/liv.16201","article-title":"Maralixibat reduces serum bile acids and improves cholestatic pruritus in adolescents with alagille syndrome","volume":"45","author":"Hirschfield","year":"2025","journal-title":"Liver Int"},{"key":"R56-20250904","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S2468-1253(24)00080-3","article-title":"Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Miethke","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R57-20250904","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jpeds.2022.09.001","article-title":"Maralixibat treatment response in alagille syndrome is associated with improved health-related quality of life","volume":"252","author":"Kamath","year":"2023","journal-title":"J Pediatr"},{"key":"R58-20250904","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1097\/HEP.0000000000000502","article-title":"Predictors of 6-year event-free survival in Alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor","volume":"78","author":"Sokol","year":"2023","journal-title":"Hepatology"},{"key":"R59-20250904","doi-asserted-by":"crossref","first-page":"100782","DOI":"10.1016\/j.jhepr.2023.100782","article-title":"Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis","volume":"5","author":"Thompson","year":"2023","journal-title":"JHEP Rep"},{"issue":"(Suppl 3)","key":"R60-20250904","first-page":"A13","article-title":"P1 Analysis of long-term treatment effects of odevixibat on clinical outcomes in children with progressive familial intrahepatic cholestasis in odevixibat clinical studies vs external controls from the NAPPED database","volume":"72","author":"Hansen","year":"2023","journal-title":"Gut"},{"key":"R61-20250904","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/s41575-024-01008-w","article-title":"Bile acid transport inhibitors in paediatric hepatology: more than just an itch","volume":"21","author":"Diamond","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R62-20250904","first-page":"949","article-title":"Surgical versus medical management of progressive familial intrahepatic cholestasis-case compilation and review of the literature","volume":"10","author":"Hupper","year":"2023","journal-title":"Children (Basel)"},{"key":"R63-20250904","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/LVT.0000000000000351","article-title":"Simultaneous total internal biliary diversion during liver transplantation for progressive familial intrahepatic cholestasis type 1: Standard of care?","volume":"30","author":"Menon","year":"2024","journal-title":"Liver Transpl"},{"key":"R64-20250904","doi-asserted-by":"crossref","first-page":"e14600","DOI":"10.1111\/petr.14600","article-title":"Outcomes of pediatric liver transplantation for progressive familial intrahepatic cholestasis","volume":"27","author":"Vasudevan","year":"2023","journal-title":"Pediatr Transplant"},{"key":"R65-20250904","doi-asserted-by":"crossref","first-page":"e0286","DOI":"10.1097\/HC9.0000000000000286","article-title":"Management and outcomes after liver transplantation for progressive familial intrahepatic cholestasis: a systematic review and meta-analysis","volume":"7","author":"Kavallar","year":"2023","journal-title":"Hepatol Commun"},{"key":"R66-20250904","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.32761","article-title":"Natural history of liver disease in a large international cohort of children with Alagille syndrome: results from the GALA study","volume":"77","author":"Vandriel","year":"2023","journal-title":"Hepatology"},{"key":"R67-20250904","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/14728214.2024.2336986","article-title":"Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials","volume":"29","author":"Hof","year":"2024","journal-title":"Expert Opin Emerg Drugs"},{"key":"R68-20250904","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/HEP.0000000000000376","article-title":"A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans","volume":"78","author":"Caballero-Camino","year":"2023","journal-title":"Hepatology"},{"key":"R69-20250904","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/HEP.0000000000000473","article-title":"Choluresis?","volume":"78","author":"Thompson","year":"2023","journal-title":"Hepatology"},{"key":"R70-20250904","doi-asserted-by":"crossref","first-page":"1506195","DOI":"10.3389\/fimmu.2025.1506195","article-title":"Transcriptional analysis of murine biliary atresia identifies macrophage heterogeneity and subset-specific macrophage functions","volume":"16","author":"Gromer","year":"2025","journal-title":"Front Immunol"},{"key":"R71-20250904","doi-asserted-by":"crossref","DOI":"10.1038\/s41390-025-03804-9","article-title":"Increased serum GM-CSF at diagnosis of biliary atresia is associated with improved biliary drainage","author":"Taylor","year":"2025","journal-title":"Pediatr Res"},{"key":"R72-20250904","article-title":"Interleukin 8-CXCR2-mediated neutrophil extracellular trap formation in biliary atresia associated with neutrophil extracellular trap-induced stellate cell activation","author":"Luo","year":"2024","journal-title":"Hepatology"},{"key":"R73-20250904","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41572-024-00533-x","article-title":"Biliary atresia","volume":"10","author":"Tam","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"R74-20250904","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1055\/a-2153-8927","article-title":"Genetic contributions to biliary atresia: a developmental cholangiopathy","volume":"43","author":"Hellen","year":"2023","journal-title":"Semin Liver Dis"},{"key":"R75-20250904","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jhep.2023.07.039","article-title":"Biliary atresia is associated with polygenic susceptibility in ciliogenesis and planar polarity effector genes","volume":"79","author":"Glessner","year":"2023","journal-title":"J Hepatol"},{"key":"R76-20250904","doi-asserted-by":"crossref","first-page":"151474","DOI":"10.1016\/j.sempedsurg.2025.151474","article-title":"Immunology of biliary atresia","volume":"33","author":"Miller","year":"2024","journal-title":"Semin Pediatr Surg"},{"key":"R77-20250904","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s00431-023-04925-1","article-title":"Age at surgery and native liver survival in biliary atresia: a systematic review and meta-analysis","volume":"182","author":"Hoshino","year":"2023","journal-title":"Eur J Pediatr"},{"key":"R78-20250904","doi-asserted-by":"crossref","first-page":"162250","DOI":"10.1016\/j.jpedsurg.2025.162250","article-title":"Real-world multiinstitutional data from the Midwest Pediatric Surgery Consortium (MWPSC) to assess the effect of delayed kasai procedure on biliary drainage in patients with biliary atresia","volume":"60","author":"Farooqui","year":"2025","journal-title":"J Pediatr Surg"},{"key":"R79-20250904","doi-asserted-by":"crossref","first-page":"e0307837","DOI":"10.1371\/journal.pone.0307837","article-title":"Population-based screening strategies for biliary atresia in the newborn: a systematic review and meta-analysis","volume":"19","author":"Gopal","year":"2024","journal-title":"PLoS One"},{"key":"R80-20250904","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jama.2020.0837","article-title":"Diagnostic yield of newborn screening for biliary atresia using direct or conjugated bilirubin measurements","volume":"323","author":"Harpavat","year":"2020","journal-title":"JAMA"},{"key":"R82-20250904","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/HEP.0000000000000827","article-title":"Diagnostic accuracy of serum matrix metalloproteinase-7 as a biomarker of biliary atresia in a large North American cohort","volume":"80","author":"Pandurangi","year":"2024","journal-title":"Hepatology"},{"key":"R83-20250904","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1186\/s12967-024-05442-x","article-title":"Serum matrix metalloproteinase-7 for discriminating biliary atresia: a diagnostic accuracy and validation study","volume":"22","author":"Jiang","year":"2024","journal-title":"J Transl Med"},{"key":"R84-20250904","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00383-024-05730-z","article-title":"Comparison for the diagnostic performance of early diagnostic methods for biliary atresia: a systematic review and network meta-analysis","volume":"40","author":"Zhang","year":"2024","journal-title":"Pediatr Surg Int"},{"key":"R85-20250904","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1053\/j.gastro.2024.09.035","article-title":"Prospective analysis of liver stiffness measurement by vibration controlled transient elastography as a predictor of outcomes in biliary atresia","volume":"168","author":"Molleston","year":"2025","journal-title":"Gastroenterology"},{"key":"R86-20250904","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/hep.32800","article-title":"Serum bile acids as a prognostic biomarker in biliary atresia following Kasai portoenterostomy","volume":"77","author":"Harpavat","year":"2023","journal-title":"Hepatology"},{"key":"R87-20250904","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1097\/HEP.0000000000000048","article-title":"Serum FGF19 predicts outcomes of Kasai portoenterostomy in biliary atresia","volume":"77","author":"Nyholm","year":"2023","journal-title":"Hepatology"},{"key":"R88-20250904","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00383-022-05115-0","article-title":"Study protocol of Phase 2 open-label multicenter randomized controlled trial for granulocyte-colony stimulating factor (GCSF) in post-Kasai Type 3 biliary atresia","volume":"38","author":"Nguyen","year":"2022","journal-title":"Pediatr Surg Int"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T08:00:18Z","timestamp":1756972818000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":86,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001489","relation":{},"ISSN":["1531-698X"],"issn-type":[{"type":"electronic","value":"1531-698X"}],"subject":[],"published":{"date-parts":[[2025,7,30]]}}}